Eamonn Martin Quigley, MD

David M. Underwood Chair of Medicine in Digestive Disorders, Department of Medicine
Professor of Medicine, Institute for Academic Medicine
Director, Lynda K. and David M. Underwood Center for Digestive Disorders
Houston Methodist
Weill Cornell Medical College


Dr. Eamonn M. M. Quigley, past president of the American College of Gastroenterology and the World Gastroenterology Organization, joined the faculty at Houston Methodist Hospital as head of its Gastroenterology and Hepatology division in 2013.

Prior to his move to Houston, Quigley was professor of medicine and human physiology and a principal investigator at the Alimentary Pharmabiotic Centre at the National University of Ireland in Cork. He is internationally known for his research on gastrointestinal motility disorders, primarily irritable bowel syndrome (IBS); gastroesophageal reflux disease (GERD); neurogastroenterology (the relationship between the central nervous system and the gut); the gut microbiome and probiotics in health and disease. A highlight of his ongoing research includes how bacteria in the digestive tract play a major role in pulling nutrients from food to nourish the body, as well as participating in protecting the body from disease.

IBS is the most common, chronic medical condition in the United States. Approximately 40 percent of those with IBS have symptoms severe or frequent enough to disrupt their daily lives. While the cause of IBS has not been clearly identified, Quigley’s clinical research suggests that an alteration of the normal gut bacteria flora may be a cause. His research team is working toward developing new biomarkers for IBS which would eventually lead to the development of new treatments. Quigley’s clinical interests focus on the use of probiotics for the treatment of IBS.

He has published more than 800 peer-reviewed articles, reviews, editorials, book chapters and case reports, mostly in the areas of gut motility, functional gastrointestinal disorders, and GERD. Quigley has received numerous international honors and awards. He served as Editor-in-Chief of the American Journal of Gastroenterology from 1997 to 2003.

Quigley received his medical degree from  University College Cork in Cork, Ireland; completed internal medicine residency in Glasgow, Scotland; and did GI fellowship training at the Mayo Clinic and the University of Manchester in England.  He served as the Chief of Gastroenterology at the University of Nebraska from 1991 to 1998 and as Dean of the Medical School in Cork, Ireland from 2000 to 2007.

Description of Research

Some of his pioneering research over the past several decades has included how the function of the gut is affected in a variety of diseases and conditions, including chronic liver disease, high-dose chemoradiotherapy, intestinal failure and transplantation, and Parkinson’s disease.

Areas Of Expertise

Gastroesophageal Reflux Esophageal disorders/dysphagia Gastrointestinal motility disorders Functional GI disorders Irritable bowel syndrome Gastroparesis Constipation Diarrheal disorders Celiac disease Intestinal & colonic disorders Inflammatory bowel disease/colitis/Crohn's disease General gastroenterology EGD and colonoscopy Capsule endoscopy
Education & Training

Clinical Fellowship, University of Manchester
Residency, Western Infirmary & Associates Hospital
Internship, St. Finbarr's Hospital
MD, National University of Ireland;

A Probiotic for Ulcerative Colitis: The Culture Wars Continue
Abraham, BP & Quigley, EMM 2018, Digestive Diseases and Sciences, pp. 1-3. DOI: 10.1007/s10620-018-5097-1

Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective
Giron, F & Quigley, EMM 2018, Journal of Neurogastroenterology and Motility. DOI: 10.5056/jnm18004

Therapeutic implications of the gastrointestinal microbiome
Kayshap, PC & Quigley, EMM 2018, Current Opinion in Pharmacology. DOI: 10.1016/j.coph.2018.01.004

Definition, Pathogenesis, and Management of That Cursed Dyspepsia
Koduru, P, Irani, M & Quigley, EMM 2018, Clinical Gastroenterology and Hepatology, vol 16, no. 4, pp. 467-479. DOI: 10.1016/j.cgh.2017.09.002

Are diets the answers to colon ills? Food, irritable bowel syndrome and the microbiome
Quigley, EMM 2018, Current Opinion in Gastroenterology, vol 34, no. 2, pp. 103-104. DOI: 10.1097/MOG.0000000000000420

A critical review of the current clinical landscape of gastroparesis
Fosso, CL & Quigley, EMM 2018, Gastroenterology and Hepatology, vol 14, no. 3, pp. 140-145.

Carbohydrate Maldigestion and Malabsorption
Omer, A & Quigley, EMM 2018, Clinical Gastroenterology and Hepatology. DOI: 10.1016/j.cgh.2018.01.048

The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS)
Quigley, EMM 2018, Journal of Clinical Sleep Medicine, vol 7, no. 1. DOI: 10.3390/jcm7010006

The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region - background and recommendations of a regional consensus meeting
Ghoshal, UC, Gwee, KA, Holtmann, G, Li, Y, Park, SJ, Simadibrata, M, Sugano, K, Wu, K, Quigley, EMM & Cohen, H 2018, Journal of Gastroenterology and Hepatology (Australia), vol 33, no. 1, pp. 57-69. DOI: 10.1111/jgh.13840

Microbiota-Brain-Gut Axis and Neurodegenerative Diseases
Quigley, EMM 2017, Current Neurology and Neuroscience Reports, vol 17, no. 12, 94. DOI: 10.1007/s11910-017-0802-6

The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference
Yiannakou, Y, Tack, J, Piessevaux, H, Dubois, D, Quigley, EMM, Ke, MY, Da Silva, S, Joseph, A & Kerstens, R 2017, Alimentary Pharmacology and Therapeutics, vol 46, no. 11-12, pp. 1103-1111. DOI: 10.1111/apt.14349

Probiotics in Inflammatory Bowel Disease
Abraham, BP & Quigley, EMM 2017, Gastroenterology Clinics of North America. DOI: 10.1016/j.gtc.2017.08.003

The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire
Harris, LA, Horn, J, Kissous-Hunt, M, Magnus, L & Quigley, EMM 2017, Advances in Therapy, pp. 1-13. DOI: 10.1007/s12325-017-0633-5

An update on prucalopride in the treatment of chronic constipation
Omer, A & Quigley, EMM 2017, Therapeutic Advances in Gastroenterology, vol 10, no. 11, pp. 877-887. DOI: 10.1177/1756283X17734809

Prokinetics in the Management of Functional Gastrointestinal Disorders
Quigley, EMM 2017, Current Gastroenterology Reports, vol 19, no. 10, 53. DOI: 10.1007/s11894-017-0593-6

Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts
Tack, J, Corsetti, M, Camilleri, M, Quigley, EM, Simren, M, Suzuki, H, Talley, NJ, Tornblom, H & Van Oudenhove, L 2017, Gut. DOI: 10.1136/gutjnl-2016-312230

Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms
Allen, AP, Clarke, G, Cryan, JF, Quigley, EMM & Dinan, TG 2017, Current Medical Research and Opinion, vol 33, no. 7, pp. 1349-1351. DOI: 10.1080/03007995.2017.1322571

Editorial: food for thought—the low-FODMAP diet and IBS in perspective
Quigley, EMM 2017, Alimentary Pharmacology and Therapeutics, vol 46, no. 2, pp. 206-207. DOI: 10.1111/apt.14140

The Role of the Microbiome and the use Of Probiotics in Gastrointestinal Disorders in Adults in the Asia-Pacific Region
Ghoshal, UC, Gwee, K-A, Holtmann, G, Li, Y, Park, SJ, Simadibrata, M, Sugano, K, Wu, K, Quigley, EMM & Cohen, H 2017, Journal of Gastroenterology and Hepatology (Australia). DOI: 10.1111/jgh.13840

Editorial: diet, inflammation and irritable bowel syndrome
Quigley, EMM 2017, Alimentary Pharmacology and Therapeutics, vol 45, no. 9, pp. 1278-1279. DOI: 10.1111/apt.14014